Ionis Pharmaceuticals (IONS) Stock Rating Reiterated at Buy

H.C. Wainwright has reiterated its buy rating for Ionis Pharmaceuticals (IONS). This reaffirmation suggests confidence in Ionis' ongoing performance and potential for future growth. While the article does not provide specific numbers or price targets, maintaining a buy rating typically implies positive expectations for the stock. This information may interest investors looking for bullish sentiment in the biotechnology sector.